Ascletis Pharma (HKG:1672) said it received promising results from Phase I clinical trials for its cholesterol drug in Australia, according to a Thursday filing with the Hong Kong bourse.
ASC47 is an adipose-targeted thyroid hormone receptor beta (THRβ) selective small molecule agonist that helps weight loss without causing muscle loss, the filing added.
The final results from the trial will be presented at a conference in 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.